Attorney General T.J. Donovan
Attention: Ryan Kriger, Assistant Attorney General

AstraZeneca

VT S.92 (Act 193, Sec.10.18 V.S.A § 4637) Reporting

Overview

In Accordance with the requirements of subsection B set forth in the VT S.92 (Act 193, Sec.10.18 V.S.A § 4637) regulation, this is AstraZeneca's 30-day post launch notice of the introduction of KOSELUGO™ (selumetinib), into the state of Vermont.

The Product

KOSELUGO™ is an orally available, inhibitor of mitogen-activated protein kinases 1 and 2 (MEK1/2) and is indicated for the treatment of pediatric patients 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).

Marketing Plans

AstraZeneca will engage 1 sales representative to cover the state of Vermont. Patient brochures as well as therapy management guides, may be left behind in offices for informational purposes.

AstraZeneca provides online resources via KOSELUGO™ US healthcare professionals and patient websites. Patients may register for the KOSELUGO™ support program via the website which will enroll them in a digital relationship marketing program to receive materials such as welcome letters, patient brochures, etc. The KOSELUGO™ patient savings program for eligible commercially insured patients will be available for patients in Vermont and can be found via AstraZeneca's Product website. KOSELUGO™ is currently only marketed in the United States.

Pricing Plans

The price for Koselugo™ (selumetinib) in Vermont will be the same across the United States.

Branded Name	Generic Name	NDC	WAC Package Price	Effective Date
Koselugo	selumetinib	00310-0610-28	$2,117.08	6/11/2021
Koselugo	selumetinib	00310-0625-28	$5,292.56	6/11/2021

When setting the price of medicines AstraZeneca aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). AstraZeneca's pricing decisions are based on many factors that reflect our commitment to patients and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore

innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value.

Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.

Estimated Volume of Patients

The estimated volume of patients that could benefit from Koselugo (selumetinib) per the indication of treatment for pediatric patients 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN) is approximately 1,556.

Breakthrough Designation

Koselugo™ (selumetinib) had approval under FDA Priority Review and receive FDA Breakthrough Designation. Koselugo™ (selumetinib) *28 count bottle* received FDA approval on May 20th, 2021, and was available on June 11th, 2021.

Date of Acquisition

Koselugo™ (selumetinib) was aquired by AstraZeneca on 12/18/2003 from Array BioPharma Inc.